PRME earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -2.44. Updated 2026-07-23.
Prime Medicine (PRME) Research Hub
Prime Medicine (PRME) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 3.13 USD (-9.80%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.44, market cap 0.55B. This hub links to the full technical, earnings and options research available for PRME.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.13 USD (-9.80%) |
| 52-week range | 2.82 USD – 4.73 USD |
| Trend regime | Range |
| 14-day RSI | 51.2 (Neutral) |
| Trailing P/E | -2.44 |
| Market cap | 0.55B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for PRME
Covered Call on PRME: how it works, illustrative setup around the real 3.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PRME: how it works, illustrative setup around the real 3.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PRME: how it works, illustrative setup around the real 3.13 USD price, max profit/loss, breakeven and when to use it. Educational.
PRME technical analysis: range, last 3.13 USD, RSI 51.2, 52w range 2.82 USD–4.73 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PRME in?
Prime Medicine (PRME) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PRME in an uptrend or downtrend?
As of 2026-09-11, PRME is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PRME's trailing P/E ratio?
PRME's trailing P/E is -2.44, with a market cap of 0.55B. See the earnings research page for full valuation detail.
When does PRME next report earnings?
PRME is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.24 USD.